Despite a challenging fiscal year, Carl Zeiss Meditec AG (CZMWF) leverages new product launches and strategic market ...

There's been a notable change in appetite for Carl Zeiss Meditec AG shares in the week since its yearly report, with the stock down 15% to €49.30. Revenues were €2.1b, approxi ...

I've made no secret about my liking for the MedTech company Carl Zeiss Meditec (OTCPK:CZMWF). This is, to my mind one of the best companies in MedTech not only due to the company's portfolio ...

Fan violence at a soccer match in Germany left 79 people injured on Saturday, local police said. Supporters of FC Carl Zeiss ...

EQS-News: Carl Zeiss Meditec AG / Key word (s): Annual Report/Annual Results Carl Zeiss Meditec closes fiscal year 2023/24 with slight decline in revenue- Adjusted EBIT forecast achieved 11.12.2024 ...

The broader Asia-Pacific region was also a weak spot, with organic growth in ophthalmology devices down 4.5% for the year, ...

ZEISS partners with Mindpeak, a pioneer in AI-powered pathology solutions, to develop an integrated Multiplex ...

The Carl Zeiss Foundation is contributing EUR 6 million to a research project on the regeneration of the nervous system at ...

Net income: €178.7m (down 39% from FY 2023). Profit margin: 8.7% (down from 14% in FY 2023). The decrease in margin was ...

RBC Capital analyst Jack Reynolds-Clark maintained a Hold rating on Carl Zeiss Meditec (0DHC – Research Report) today and set a price target of €70.00. The company’s shares closed yesterday at €58.93.